Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS – NO
نویسندگان
چکیده
منابع مشابه
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - YES.
The closer progressive multiple sclerosis (MS) is approached, the more awkward it is to define and the more slippery it is to measure. Of course on one level it is easy – if 5 years previously a person affected by MS can walk or see or balance normally, but now they walk with a stick or have a visual acuity of 6/60 or are falling over, then it is clear (to anyone) that progression has occurred,...
متن کاملImaging outcome measures for progressive multiple sclerosis trials
Imaging markers that are reliable, reproducible and sensitive to neurodegenerative changes in progressive multiple sclerosis (MS) can enhance the development of new medications with a neuroprotective mode-of-action. Accordingly, in recent years, a considerable number of imaging biomarkers have been included in phase 2 and 3 clinical trials in primary and secondary progressive MS. Brain lesion c...
متن کاملOutcome measures in amyotrophic lateral sclerosis clinical trials.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with an average survival of 3-5 years. While therapies for ALS remain limited, basic and translational ALS research has been host to numerous influential discoveries in recent years. These discoveries have led to a large pipeline of potential therapies that await testing in clinical trials. Until recently, ALS clinical trials ha...
متن کاملNovel Outcome Measures for Clinical Trials in Cystic Fibrosis
Cystic fibrosis (CF) is a common inherited condition caused by mutations in the gene encoding the CF transmembrane regulator protein. With increased understanding of the molecular mechanisms underlying CF and the development of new therapies there comes the need to develop new outcome measures to assess the disease, its progression and response to treatment. As there are limitations to the curr...
متن کاملOutcome Measures in Clinical Trials for Multiple Sclerosis
Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess the true efficacy of interventions in clinical trials. In phase III trials in MS, the traditionally used primary clinical outcome measures are the Expanded Disability Status Scale and the relapse rate. Seco...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2016
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458516671205